The genome factor in region-specific DNA damage

The DNA-reactive drug U-78779 prefers mixed A/T-G/C sequences at the nucleotide level but is region-specific for long pure AT islands at the genomic level

Maryanne C S Herzig, Karl A. Rodriguez, Alex V. Trevino, Jaroslaw Dziegielewski, Brenda Arnett, Laurence Hurley, Jan M. Woynarowski

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Bizelesin is the first anticancer drug capable of damaging specific regions of the genome with clusters of its binding sites T(A/T)4A. This study characterized the sequence- and region-specificity of a bizelesin analogue, U-78779, designed to interact with mixed A/T-G/C motifs. At the nucleotide level, U-78779 was found to prefer runs of A/Ts interspersed with 1 or 2 G/C pairs, although 25% of the identified sites corresponded to pure AT motifs similar to bizelesin sites. The in silico computational analysis showed that the preferred mixed A/T-G/C motifs distribute uniformly at the genomic level. In contrast, the secondary, pure AT motifs (A/T)6A were found densely clustered in the same long islands of AT-rich DNA that bizelesin targets. Mapping the sites and quantitating the frequencies of U-78779 adducts in model AT island and non-AT island naked DNAs demonstrated that clusters of pure AT motifs outcompete isolated mixed A/T-G/C sites in attracting drug binding. Regional preference of U-78779 for AT island domains was verified also in DNA from drug-treated cells. Thus, while the primary sequence preference gives rise to non-region-specific scattered lesions, the clustering of the minor pure AT binding motifs seems to determine region-specificity of U-78779 in the human genome. The closely correlated cytotoxic activities of U-78779 and bizelesin in several cell lines further imply that both drugs may share common cellular targets. This study underscores the significance of the genome factor in a drug's potential for region-specific DNA damage, by showing that it can take precedence over drug binding preferences at the nucleotide level.

Original languageEnglish (US)
Pages (from-to)1545-1555
Number of pages11
JournalBiochemistry
Volume41
Issue number5
DOIs
StatePublished - Feb 5 2002

Fingerprint

Genomic Islands
DNA Damage
Nucleotides
Genes
Genome
DNA
Pharmaceutical Preparations
Islands
bizelesin
Cells
Human Genome
Computer Simulation
Cluster Analysis
Binding Sites

ASJC Scopus subject areas

  • Biochemistry

Cite this

The genome factor in region-specific DNA damage : The DNA-reactive drug U-78779 prefers mixed A/T-G/C sequences at the nucleotide level but is region-specific for long pure AT islands at the genomic level. / Herzig, Maryanne C S; Rodriguez, Karl A.; Trevino, Alex V.; Dziegielewski, Jaroslaw; Arnett, Brenda; Hurley, Laurence; Woynarowski, Jan M.

In: Biochemistry, Vol. 41, No. 5, 05.02.2002, p. 1545-1555.

Research output: Contribution to journalArticle

Herzig, Maryanne C S ; Rodriguez, Karl A. ; Trevino, Alex V. ; Dziegielewski, Jaroslaw ; Arnett, Brenda ; Hurley, Laurence ; Woynarowski, Jan M. / The genome factor in region-specific DNA damage : The DNA-reactive drug U-78779 prefers mixed A/T-G/C sequences at the nucleotide level but is region-specific for long pure AT islands at the genomic level. In: Biochemistry. 2002 ; Vol. 41, No. 5. pp. 1545-1555.
@article{00c46bfff5db4e9a952b204cc7412e6e,
title = "The genome factor in region-specific DNA damage: The DNA-reactive drug U-78779 prefers mixed A/T-G/C sequences at the nucleotide level but is region-specific for long pure AT islands at the genomic level",
abstract = "Bizelesin is the first anticancer drug capable of damaging specific regions of the genome with clusters of its binding sites T(A/T)4A. This study characterized the sequence- and region-specificity of a bizelesin analogue, U-78779, designed to interact with mixed A/T-G/C motifs. At the nucleotide level, U-78779 was found to prefer runs of A/Ts interspersed with 1 or 2 G/C pairs, although 25{\%} of the identified sites corresponded to pure AT motifs similar to bizelesin sites. The in silico computational analysis showed that the preferred mixed A/T-G/C motifs distribute uniformly at the genomic level. In contrast, the secondary, pure AT motifs (A/T)6A were found densely clustered in the same long islands of AT-rich DNA that bizelesin targets. Mapping the sites and quantitating the frequencies of U-78779 adducts in model AT island and non-AT island naked DNAs demonstrated that clusters of pure AT motifs outcompete isolated mixed A/T-G/C sites in attracting drug binding. Regional preference of U-78779 for AT island domains was verified also in DNA from drug-treated cells. Thus, while the primary sequence preference gives rise to non-region-specific scattered lesions, the clustering of the minor pure AT binding motifs seems to determine region-specificity of U-78779 in the human genome. The closely correlated cytotoxic activities of U-78779 and bizelesin in several cell lines further imply that both drugs may share common cellular targets. This study underscores the significance of the genome factor in a drug's potential for region-specific DNA damage, by showing that it can take precedence over drug binding preferences at the nucleotide level.",
author = "Herzig, {Maryanne C S} and Rodriguez, {Karl A.} and Trevino, {Alex V.} and Jaroslaw Dziegielewski and Brenda Arnett and Laurence Hurley and Woynarowski, {Jan M.}",
year = "2002",
month = "2",
day = "5",
doi = "10.1021/bi011907s",
language = "English (US)",
volume = "41",
pages = "1545--1555",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - The genome factor in region-specific DNA damage

T2 - The DNA-reactive drug U-78779 prefers mixed A/T-G/C sequences at the nucleotide level but is region-specific for long pure AT islands at the genomic level

AU - Herzig, Maryanne C S

AU - Rodriguez, Karl A.

AU - Trevino, Alex V.

AU - Dziegielewski, Jaroslaw

AU - Arnett, Brenda

AU - Hurley, Laurence

AU - Woynarowski, Jan M.

PY - 2002/2/5

Y1 - 2002/2/5

N2 - Bizelesin is the first anticancer drug capable of damaging specific regions of the genome with clusters of its binding sites T(A/T)4A. This study characterized the sequence- and region-specificity of a bizelesin analogue, U-78779, designed to interact with mixed A/T-G/C motifs. At the nucleotide level, U-78779 was found to prefer runs of A/Ts interspersed with 1 or 2 G/C pairs, although 25% of the identified sites corresponded to pure AT motifs similar to bizelesin sites. The in silico computational analysis showed that the preferred mixed A/T-G/C motifs distribute uniformly at the genomic level. In contrast, the secondary, pure AT motifs (A/T)6A were found densely clustered in the same long islands of AT-rich DNA that bizelesin targets. Mapping the sites and quantitating the frequencies of U-78779 adducts in model AT island and non-AT island naked DNAs demonstrated that clusters of pure AT motifs outcompete isolated mixed A/T-G/C sites in attracting drug binding. Regional preference of U-78779 for AT island domains was verified also in DNA from drug-treated cells. Thus, while the primary sequence preference gives rise to non-region-specific scattered lesions, the clustering of the minor pure AT binding motifs seems to determine region-specificity of U-78779 in the human genome. The closely correlated cytotoxic activities of U-78779 and bizelesin in several cell lines further imply that both drugs may share common cellular targets. This study underscores the significance of the genome factor in a drug's potential for region-specific DNA damage, by showing that it can take precedence over drug binding preferences at the nucleotide level.

AB - Bizelesin is the first anticancer drug capable of damaging specific regions of the genome with clusters of its binding sites T(A/T)4A. This study characterized the sequence- and region-specificity of a bizelesin analogue, U-78779, designed to interact with mixed A/T-G/C motifs. At the nucleotide level, U-78779 was found to prefer runs of A/Ts interspersed with 1 or 2 G/C pairs, although 25% of the identified sites corresponded to pure AT motifs similar to bizelesin sites. The in silico computational analysis showed that the preferred mixed A/T-G/C motifs distribute uniformly at the genomic level. In contrast, the secondary, pure AT motifs (A/T)6A were found densely clustered in the same long islands of AT-rich DNA that bizelesin targets. Mapping the sites and quantitating the frequencies of U-78779 adducts in model AT island and non-AT island naked DNAs demonstrated that clusters of pure AT motifs outcompete isolated mixed A/T-G/C sites in attracting drug binding. Regional preference of U-78779 for AT island domains was verified also in DNA from drug-treated cells. Thus, while the primary sequence preference gives rise to non-region-specific scattered lesions, the clustering of the minor pure AT binding motifs seems to determine region-specificity of U-78779 in the human genome. The closely correlated cytotoxic activities of U-78779 and bizelesin in several cell lines further imply that both drugs may share common cellular targets. This study underscores the significance of the genome factor in a drug's potential for region-specific DNA damage, by showing that it can take precedence over drug binding preferences at the nucleotide level.

UR - http://www.scopus.com/inward/record.url?scp=0037022184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037022184&partnerID=8YFLogxK

U2 - 10.1021/bi011907s

DO - 10.1021/bi011907s

M3 - Article

VL - 41

SP - 1545

EP - 1555

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 5

ER -